Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
Status:
Enrolling by invitation
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Multiple myeloma is an incurable blood cancer of plasma cells that occurs in older
individuals. Novel agents (proteasome inhibitors, immunomodulatory agents) have substantially
improved the overall response rates, progression-free survival and overall survival in
patients with multiple myeloma. Patients with multiple myeloma are at high risk of developing
life-threatening Streptococcus pneumoniae infections, while clinical efficacy and safety of
conjugate pneumococcal vaccines in multiple myeloma patients receiving novel agents have not
been studied before. The main aim of this study is to assess the clinical efficacy and safety
of 13-valent pneumococcal conjugate vaccine in multiple myeloma patients treated with novel
agents.
Phase:
Phase 4
Details
Lead Sponsor:
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology Minsk State Clinical Hospital No 9